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Background and aims Familial hypercholesterolemia (FH) is at very high
risk of early myocardial infarction (MI). The prevalence of FH, which is esti-
mated to be at least 1:500 in the general population, remains unclear in
patients with acute MI. From databases of 2 French regional and nationwide
registries of acute MI (RICO and FAST-MI, respectively), we aimed to deter-
mine FH prevalence by developing a specific algorithm.
Methods and results Consecutive patients with AMI ≤48 hours of onset
included 1) in FAST-MI: during a one-month period in 213 institutions at the
end of 2005 and 2) in RICO: from January 2001 December 2013 (≈13y), were
considered in the 2 databases. The algorithm was adapted from Dutch lipid
clinic network criteria and was build upon 4 variables (i.e. LDL level and pre-
vious use of lipid lowering medications, premature and family history) to
identify FH probability. The LDL level was adjusted on each type of lipid
lowering medications and the probability of FH was defined taking into
account missing data rate. Among the 7484 patients included in the RICO reg-
istry, 29.1% had premature vascular disease, 29.7% had familial history,
19.9% were under lipid lowering medications and 9.7% had LDL ≥5mmol/L.
FH prevalence was calculated as unlikely (72.6%), possible (24.6%) and prob-
able /definite (2.8%).
Conclusion Our 4-variables algorithm is relevant to determine FH proba-
bility in databases from MI registries. In this large population reflecting rou-
tine clinical practice in acute MI, a high prevalence of FH was found,
suggesting the opportunity for prevention strategies.
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Objectives To describe the characteristics and treatments of patients
having a myocardial infarction (MI) and estimate the incidence of cardio-
vascular events following the index MI, in the French Health Insurance
database.
Method A cohort of patients who had a MI in France between 2007 and
2011 was extracted from a claim database: the Echantillon Généraliste de
Bénéficiaires (a 1% representative sample of subjects covered by the gen-
eral health insurance (?600,000 patients). The incidence of cardiovascular
events following the index MI was estimated using the Kaplan Meier
method. 
Results 1,977 subjects were identified with an index myocardial MI: 2/3
were males, mean age=67.2 y, 20.6% had diabetes, 37.6% hypercholesterol-
emia and 82.4% hypertension. Cumulative incidence rates for outcomes are
shown in the table. All cause mortality at 3 years (including in-hospital death)
was 27% (95% CI: 25.8-29.1). This incidence was high in the 3 months fol-
lowing the index MI stabilized thereafter. 
Conclusion Despite high prescription rates of post-MI treatments, rates of
all-cause mortality and CV events remained high following MI. This under-
scores the need to improve secondary prevention. 
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Background Obstructive Sleep Apnea (OSA) is frequently associated
with cardiovascular disease. Its diagnosis seems to be related with poor
prognosis. 
Aim To determine the prevalence of OSA in patients with acute coronary
syndrome (ACS). Evaluate the prognostic impact of OSA and CPAP therapy
in these patients. 
Methods Prospective study of 73 patients diagnosed with ACS. A poly-
somnography was performed in all patients. An Apnea-hypopnea index >5
was considered diagnostic of OSA and patients were referred to CPAP
therapy. We evaluated the occurrence of the primary composite endpoint of
death, myocardial infarction and revascularization. 
Results The prevalence of OSA was 63.0%. The average age
(62.4±11.3) was similar in both groups. Gender and cardiovascular risk
factors were not significantly different between groups. Patients were
admitted for Non-ST elevation ACS in 60.3% and for ST elevation ACS
Abstratct 0053 – Table
% patients treated
6 months 
before index MI
6 months 
after index MI
Statins 30.7% 91.1%
Ezetimibe 3.6% 4.9%
Aspirine (Alone) 59.9% 11.6%
Aspirine+P2Y12-I* 23.9% 76.0%
Class III Antiarrhytmic 2.4% 8.4%
Oral Anticoagulant 5.1% 10.1%
Non-Thiazide Diuretics 19.1% 32.9%
ACE Inhibitors 18.6% 71.0%
Beta-Blockers 26.5% 86.0%
Nitrates 9.9% 46.4%
Other Antihypertensives** 40.2% 30.3%
Cumulative incidence rate (95%CI)
1 year 2 year 3 year
All cause deaths*** 17.8% 
(16.0%;19.5%)
21.6% 
(20.7%;23.5%)
27.0%
(25.8%;29.1%)
Recurrent MI 3.1% 
(2.3%;3.8%)
4.1% 
(3.2%;5.0%)
4,7% 
(3.7%;5.7%)
Stroke orTIA 1.9% 
(1.3%;2.5%)
3.1% 
(2.3%;3.9%)
4.1% 
(3.1%;5.0%)
Composite of death***/
reinfarction/stroke
20.7% 
(18.9%;22.5%)
26.0% 
(24.0%;28.0%)
32.1%
(29.8%;34.3%)
* mostly clopidogrel
**thiazide diuretics, angiotensin II receptor blockers, CCBs
*** including in-hospital deaths
